Want to join the conversation?
Biotechnology pioneer $AMGN said it recorded 17% growth from its in-line brands, including Enbrel, Prolia, XGEVA, Sensipar, Vectibix and Nplate. Together, these brands generated $11Bil. The company stated that its legacy medicines also performed well and these continue to be strong cash flow generators.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.